Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05274451 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate LYL797 in Adults With Solid Tumors
A Phase 1 study, sponsored by Lyell Immunopharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT05274451: Clinical Trial Phase 1 study, sponsored by Lyell Immunopharma.
NCT05274451 is a Phase 1 study that was terminated before completion, run by Lyell Immunopharma. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05274451, a Phase 1 study, was terminated before completion, sponsored by Lyell Immunopharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer (Ovarian cancer), or Endometrial cancer. The first part of the study will determine the safe dose for the next part of the study, and will enroll patients with TNBC, NSCLC, Ovarian or Endometrial cancer. The second part of the study will test that dose in additional patients with TNBC, NSCLC, Ovarian or Endometrial cancer.
Primary Outcome
Incidence of dose-limiting toxicities (DLTs)
Interventions
- BIOLOGICAL LYL797
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2024-11-27 |
| Phase | Phase 1 |
Why NCT05274451 stopped before completion
NCT05274451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which LYL797 is the first listed.
NCT05274451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05274451 about?
NCT05274451 is a clinical study titled "A Study to Investigate LYL797 in Adults With Solid Tumors". This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary per...
What is the current status of trial NCT05274451?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2022-03-29. Estimated completion is 2024-11-27.
What interventions are being tested in trial NCT05274451?
The interventions under investigation include: LYL797 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05274451?
This trial is sponsored by Lyell Immunopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05274451's enrollment target sits among peer trials
57 901st of 2000 higher than 1,099 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI